Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, and Efficacy of GS-9876 in Participants With Active Rheumatoid Arthritis on Background Therapy With Methotrexate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~* Active RA disease as defined by: a tender joint count (TJC) of ≥ 6 (out of 68), a swollen joint count (SJC) of ≥ 6 (out of 66) at screening and Day 1~* Inadequate response to treatment with oral or parenteral methotrexate (MTX) 7.5 to 25 mg/week continuously for at least 12 weeks~* No evidence of active or latent tuberculosis~Key Exclusion Criteria:~* Prior treatment with B-cell depleting agents (eg, rituximab), unless more than 6 months prior to the first dose of study drug and documented return of CD19+ cells at screening~* Prior treatment with any commercially available or investigational spleen tyrosine kinase (SYK) inhibitor~* Concurrent treatment with any other conventional synthetic DMARD (csDMARD) other than MTX and/or hydroxychloroquine (HCQ) (prior csDMARD treatment allowed if appropriate wash out as defined in the protocol)~* Concurrent treatment with any biological disease modifying anti-rheumatic drug (bDMARD)(prior bDMARD treatment allowed if appropriate wash out as defined in the protocol). Prior failure to treatment with bDMARDs is not an exclusion criterion.~Note: Other protocol defined Inclusion/ Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- GS-9876 - 30 mg (Type: EXPERIMENTAL): GS-9876 30 mg + filgotinib placebo for 12 weeks
- GS-9876 - 10 mg (Type: EXPERIMENTAL): GS-9876 10 mg + filgotinib placebo for 12 weeks
- Filgotinib (Type: EXPERIMENTAL): Filgotinib + GS-9876 placebo for 12 weeks
- Placebo (Type: PLACEBO_COMPARATOR): GS-9876 placebo + filgotinib placebo for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).